Meeting
2023 ASCO Annual Meeting
A phase 2 randomized study of magrolimab combination therapy in adult patients with unresectable locally advanced or metastatic triple-negative breast cancer (mTNBC): ELEVATE-TNBC.
Authors
Natalie Rainey
Cairns and Hinterland Hospital and Health Service, Cairns, QLD, Australia
Natalie Rainey , Rohit Joshi , Joanne Chiu , Ann Chen , Hao Wang , Jared Odegard , Estibaliz Lopez Rodrigo , Sylvia Adams
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Breast Cancer—Metastatic
Track
Breast Cancer
Sub Track
Triple-Negative
Clinical Trial Registration Number
NCT04958785
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr TPS1130)
DOI
10.1200/JCO.2023.41.16_suppl.TPS1130
Abstract #
TPS1130
Poster Bd #
341b
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
A phase 2 multi-arm study of magrolimab in combination with docetaxel in patients with locally advanced or metastatic solid tumors: ELEVATE Lung and UC.
First Author: Vivek Subbiah
Poster
2023 ASCO Annual Meeting
A phase 2 study of magrolimab combination therapy in patients with recurrent or metastatic head and neck squamous cell carcinoma: ELEVATE HNSCC.
First Author: A. Dimitrios Dimitrios Colevas
Poster
2021 ASCO Annual Meeting
Saci-IO TNBC: Randomized phase II trial of sacituzumab govitecan (SG) +/- pembrolizumab in PD-L1– metastatic triple-negative breast cancer (mTNBC).
First Author: Ana Christina Garrido-Castro
Poster
2020 Genitourinary Cancers Symposium
FIDES-02, a phase Ib/II study of derazantinib (DZB) as monotherapy and combination therapy with atezolizumab (A) in patients with surgically unresectable or metastaticurothelial cancer (UC) and FGFR genetic aberrations.
First Author: Arvind Chaudhry